Table 1 Characteristics of included studies in the meta-analysis
From: Periodontitis and inflammatory bowel disease: a meta-analysis
Author (Year) | Location | Study design | Matched variables | Participants (M/F, age) | IBD (M/F) | Periodontal measures | Pharmacological treatments | Smoking | Adjusted variables | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
Groessner-Schreiber, et al. (2006) | Germany | Matched case–control study | Age; sex; smoking status | IBD:62 (24/38, 38.4) Control:59 (24/35, 38.2) | CD:46 (18/28) UC: 16 (4/12) | PI; BOP; PPD; CAL ≥ 4 mm; CAL ≥ 5 mm | Corticosteroids; immunosuppressants; aminosalicylate; anti TNF Antibiotics | IBD nonsmokers = 34 (55%); smokers = 25; ex-smokers = 3 (5%) Control nonsmokers =29 (49%); smokers = 24; ex-smokers = 6 (10%) | NA | 7 |
Zervou, et al. (2007) | Greece | Matched case–control study | Age; sex | IBD:30 Control:47 | CD: 15 UC: 15 | Periodontitis | Mesalazine; aziathioprine | OR (95%CI) nonsmokers = 1.00; smokers = 0.99 (0.11–0.63); ex-smokers = 0.61 (0.06–6.29) | Sex; smoking habit; activity duration of disease | 6 |
Brito, et al. (2008) | Brazil | Matched case–control study | Age | IBD:179 (64/115) Control:74 (24/50, 40.3) | CD:99 (31/68) UC:80 (33/47) | BOP; PPD; CAL ≥ 3 mm | Aminosalicylates; immunomodulaors; corticosteroidds; antibiotics; anti TNF-α | CD smokers = 12 (12.1%); nonsmokers = 63 (63.3%); ex-smokers = 24 (24.3%). UC smokers = 7 (8.7%); nonsmokers = 38 (47.5%); ex-smokers = 35 (43.8%) Control smokers = 9 (12.2%); nonsmokers = 57 (77%); ex-smokers = 8 (10.8%) | NA | 7 |
Habashneh, et al. (2012) | Jordan | Case–control study | NA | IBD:160 (94/66) Control:100 (62/38) | CD:59 (33/26) UC:101 (61/40) | PI; GI; PPD; CAL; GR; BOP; PPD ≥ 3; PPD ≥ 4; CAL ≥ 3; CAL ≥ 4; CAL ≥ 5 | NA | CD nonsmokers = 23; smokers = 31; ex-smokers = 5 UC nonsmokers = 55; smokers = 17; ex-smokers = 29 Control nonsmokers = 44; smokers = 49; ex-smokers = 7 | NA | 7 |
Vavricka, et al. (2013) | Switzerland | Matched case–control study | Age | IBD:113 (65/48, 40.6) Control:113 (58/55, 41.7) | CD: 69 (37/32) UC: 44 (28/16) | PPD; CAL; CAL at deepest pocket; BOP; PBI | Systemic steroids; aminosalicylates; Thiopurines; methotrexate; cyclosporine; or tacrolimus; anti-TNF; probiotics; nonsteroidal; antiinflammatory drug | CD nonsmokers = 25; smokers = 21; ex-smokers = 3 UC nonsmokers = 23; smokers = 2; ex-smokers = 19 Control nonsmokers = 71; smokers = 21; ex-smokers = 21 | Perianal extraintestinal manifestation; proctitis; teeth brushing≥twice/day; ex-smoking; HBI>10; CD montreal perianal | 7 |
Koutsochristou, et al. (2015) | Greece | Matched case–control study | Age; Sex; social-economic status | IBD:55 (25/30, 12.3) Control:55 (25/30, 12.2) | CD: 36 (18/18)UC: 19 (7/12) | GI; CPI (PPD) | Aminosalicylate; corticosteroids; anti-TNF; immunomodulators | CD nonsmokers = 36; UC nonsmokers = 19; Control nonsmokers = 55 | NA | 8 |